Article Versions Notes

Hasanov M, Rioth MJ, Kendra K, Hernandez-Aya L, Joseph RW, Williamson S, Chandra S, Shirai K, Turner CD, Lewis K, et al. A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. Cancers. 2020; 12(8):2270. https://doi.org/10.3390/cancers12082270

Hasanov, Merve, Matthew J. Rioth, Kari Kendra, Leonel Hernandez-Aya, Richard W. Joseph, Stephen Williamson, Sunandana Chandra, Keisuke Shirai, Christopher D. Turner, Karl Lewis, and et al. 2020. "A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma" Cancers 12, no. 8: 2270. https://doi.org/10.3390/cancers12082270

Hasanov, M., Rioth, M. J., Kendra, K., Hernandez-Aya, L., Joseph, R. W., Williamson, S., Chandra, S., Shirai, K., Turner, C. D., Lewis, K., Crowley, E., Moscow, J., Carter, B., & Patel, S. (2020). A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. Cancers, 12(8), 2270. https://doi.org/10.3390/cancers12082270